Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T‐cell acute lymphoblastic leukemia harboring a cryptic ETV6‐NTRK3 fusion

Abstract

AbstractOutcomes for patients with relapsed and refractory (R/R) T‐cell acute lymphoblastic leukemia (T‐ALL) after allogeneic hematopoietic stem cell transplantation (allo‐HSCT) are dismal, with few available treatments. Recently, identification of cancer patients harboring neurotrophic tropomyosin receptor kinase (NTRK) gene fusions is constantly increasing, especially with the advent of NTRK inhibitors. However, the role of ETV6‐NTRK3 in T‐ALL has not been investigated. This case represented the first detailed report of T‐ALL patient harboring a cryptic ETV6‐NTRK3 fusion with an unfavorable prognosis, not only because of leukemia resistant to the standard multiagent chemotherapy but also early relapse after allo‐HSCT. Acquired EP300 mutation was found at relapse, which could explain the cause of recurrence and affect the follow‐up treatment. Combined targeted therapy like larotrectinib allied with pan‐targeted BCL‐2 inhibitor venetoclax, may be a potential maintenance treatment in R/R ETV6‐NTRK3 positive leukemia after allo‐HSCT. The leukemic clonal evolution might be revealed through transcriptome sequencing and overcome by drugs with universal targets. Our case demonstrated that both comprehensive profiling techniques (such as transcriptome sequencing, multiparameter flow cytometry, and digital droplet polymerase chain reaction) and a multimodality treatment strategy were critical for anticipating an early relapse and personalized therapy of R/R T‐cell leukemia.